Telecom Signaling Industry News

TMCNet:  Research and Markets: Global Non-Small Cell Lung Cancer Market to 2020: Pipeline Entries to Drive NSCLC Market Growth

[August 19, 2014]

Research and Markets: Global Non-Small Cell Lung Cancer Market to 2020: Pipeline Entries to Drive NSCLC Market Growth

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market" report to their offering.

The Non-Small Cell Lung Cancer (NSCLC) market will undergo considerable growth from $5.1 billion in 2013 to $7.9 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 6.6%.

The added value will be derived from an abundance of new product launches relatively early in the forecast period. Many of these therapies will target the second line of treatment; both the first-line treatment of patients with non-squamous histology and the maintenance setting will remain relatively unchanged by 2020. New second-line therapies include immunostimulants such as ramucirumab and nivolumab, which have shown clinical benefits, but which will face difficulties due to the increasingly crowded second-line setting. Currently, pharmaceutical treatment is limited to late-stage patients. However, vaccine therapies such as Lucanix (belagenpumatucel-L) will launch in the forecast period, for patients with stage II or IIIA NSCLC, in the currently sparse adjuvant setting. Although vaccine treatments have been unsuccessful so far in NSCLC - the most recent example being GSK's MAGE-A3 vaccine failing its Phase III trial - Lucanix has shownlarge improvements to survival rates in its initial clinical trials.

Monoclonal Antibodies to Diversify Squamous Cell Treatment

Over the forecast period to 2020, several new additions to the NSCLC treatment paradigm will transform the treatment landscape. Many of these will be monoclonal Antibodies (mAbs), which instigate an immune response to the tumor rather than directly affecting cancer cells. Crucially, some of these mAbs will be indicated for patients with squamous cell histology, whose current treatment options are very limited and primarily consist of chemotherapy. Squamous cell histology accounts for approximately 30% of the NSCLC population, and pipeline products, such as Yervoy (ipilimumab) in the first-line treatment and nivolumab in the second-line, will add greater diversity to the treatment algorithm, with both having shown clinical benefits in early-stage trials. Access to these premium treatments in this under-represented segment will be one of the primary drivers for growth in the overall NSCLC market.

Efforts are being made to understand the molecular characterization of NSCLC tumors in order to identify cancer-cell-specific targets for therapy, based on the success of targeted therapies Tarceva (erlotinib) and Xalkori (crizotinib). However, novel therapies targeting these molecules, such as Kirsten Rat Sarcoma viral oncogene homolog (KRAS), have so far been unsuccessful in the late-stage pipeline, meaning that the range of mutant signal pathway molecules targeted by therapy will remain largely unchanged over the forecast period and mAb immunotherapies targeting cancer or T-cell antigens will have a much larger impact than small-molecule-targeted signal inhibitors.

Key Topics Covered:

1 Tables & Figures

2 Introduction

  • Disease Introduction
  • Epidemiology
  • Etiology and Pathophysiology
  • Symptoms
  • Diagnosis
  • Prognosis (News - Alert)
  • Treatment

3 Marketed Products

  • Chemotherapies - Various
  • Alimta - Eli Lilly
  • Abraxane - Celgene Corporation
  • Tarceva - Roche
  • Iressa - AstraZeneca
  • Gilotrif - Boehringer Ingelheim
  • Xalkori - Pfizer
  • Avastin (bevacizumab) - Roche
  • Marketed Products Heatmap
  • Conclusion

4 NSCLC Pipeline

  • Mechanisms of Action in the Pipeline
  • Clinical Trials
  • Late-Stage Pipeline Product Profiles
  • Safety and Efficacy Heatmap
  • Conclusion

5 Market Forecast

  • Geographical Markets
  • Drivers and Barriers

6 Strategic Consolidations

  • Major Co-Development deals
  • Major Licensing Deals

7 Appendix

For more information visit

[ Back To Telecom Signaling's Homepage ]

Featured Events

5G NA Signaling Day

November 14-16, 2016
Sheraton Dallas, Dallas, TX

Featured Webcasts

Securing The Signaling Interconnect: Oracle's Perspective On Recent Security Events

Today's telecommunications landscape is changing rapidly, and the "institution" of trust between networks that has been assumed over the decades is no longer relevant. We are now hearing of vulnerabilities in CSP interconnection points that have been known ...

Applications of Wi-Fi Calling

With all of the discussion about faster data access and richer content, it could be assumed that voice services no longer play an important role in the business model of the communications service provider. Join ReThink Technologies Research and Oracle Communications as we explore ...

Featured Whitepapers

Oracle Communications Diameter Signaling Router Main Differentiators

Diameter is the protocol used by network elements in LTE and 3G networks to enable and monetize services, such as voice, video and data. Diameter enables revenue-generating data services; including tiered data plans, loyalty programs, application specific QoS, content provider and Internet of Things (IoT) solutions ...

Multi-Layer Security Protection for Signaling Networks

The sanctity of mobile operators' networks and brands will depend greatly on their ability to deliver QoS guarantees to roaming and interconnect partners, while simultaneously protecting increasingly multimedia-savvy and socially connected ...

Featured Datasheets

Oracle Communications Diameter Signaling Router

Centralizing Diameter routing with cloud deployable Oracle Communications Diameter Signaling Router creates a secure signaling architecture that reduces the cost and complexity of the core network and enables elastic growth, interoperability and rapid introduction ...

Oracle Communications Mobile Security Gateway

The Oracle Communications Mobile Security Gateway is a high performance gateway that allows the Communications Service Provider (CSP) to cost effectively expand network coverage and increase capacity by incorporating Heterogeneous ...

Oracle Communications Evolved Communications Application Server

As service providers drive their networks toward an all-IP and virtualized state, they require the means to design and deliver compelling high definition voice, video and multimedia offers via Voice over LTE (VoLTE) and Voice over WiFi (VoWiFi) ...

Featured Infographic